All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Jessica Donington, MD
Disclosure(s): Amgen Inc.: Advisory Board (Terminated, October 20, 2023)

Luis Tapias, MD
Disclosure(s): Astra Zeneca: Advisory Board (Terminated); Atricure: Advisory Board (Ongoing); Intuitive Surgical, Inc.: Consultant (Ongoing)

Presentations

1. Neoadjuvant and "Sandwich" Lung Cancer Trials
   Jonathan David Spicer, MD, PhD, FRCSC
   Disclosure(s): Amgen: Advisory Board (Ongoing), Speaker (Ongoing); Astrazeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CLS Therapeutics: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eisai: Advisory Board (Terminated); MSD: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Protalix Biotherapeutics: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Regeneron: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche: Advisory Board (Terminated), Consultant (Terminated), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); xenetic biosciences: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
    
2. Limited Uptake of Adjuvant Chemotherapy for Stage II-III Non-Small-Cell Lung Cancer in the United States: Implications for Adherence to Novel Adjuvant Treatment Modalities
   Arvind Kumar
    
3. Adjuvant Lung Cancer Trials
   Brendon Stiles, MD
   Disclosure(s): , Medtronic: Consultant (Ongoing), Speaker (Ongoing); American Cancer Society: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Arcus Biosciences: Advisory Board (Terminated); Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing); BMS: Advisory Board (Ongoing); BMS Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Galvanize Therapeutics Inc: Consultant (Ongoing); Lung Cancer Research Foundation: Board member (Ongoing); Merck & Co.: Advisory Board (Ongoing), Consultant (Ongoing); Pfizer, USA: Advisory Board (Ongoing), Consultant (Ongoing); Regeneron: Consultant (Ongoing); Roche Genentech: Advisory Board (Ongoing), Consultant (Ongoing); Xalud Therapeutics: Employee (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
    
4. Outcomes of Patients with cT3-4N2 NSCLC in the Era of Modern Systemic Therapy: Is it Time to Redefine Resectability?
   Jorge Humberto Rodriguez Quintero, MD
    
5. Revisiting N3 Non-Small Cell Lung Cancer: Assessing Survival Parallels to N2 Disease and the Impact of Neoadjuvant Therapy with Surgery
   Aria Bassiri, MD
    
6. Stage III Trials
   Linda W. Martin, MD, MPH
   Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon: Speaker (Ongoing); Genentech: Advisory Board (Ongoing), Speaker (Ongoing); ontarget laboratories: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
7. Tumor Board Discussion
   Jonathan David Spicer, MD, PhD, FRCSC
   Brendon Stiles, MD
   Linda W. Martin, MD, MPH